Tailored Melatonin- and Donepezil-Based Hybrids Targeting Pathognomonic Changes in Alzheimer’s Disease: An In Vitro and In Vivo Investigation
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25115969 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Rositsa Mihaylova und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department "Pharmacology, Pharmacotherapy and Toxicology", Faculty of Pharmacy, Medical University of Sofia, 1431 Sofia, Bulgaria. Hauptthemen laut MEDLINE: Donepezil, Alzheimer Disease, Melatonin, Amyloid beta-Peptides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Bulgarian National Science Fund, Bulgarian National Science Fund.
Themen: Demenz
Abstract (Originalsprache)
A plethora of pathophysiological events have been shown to play a synergistic role in neurodegeneration, revealing multiple potential targets for the pharmacological modulation of Alzheimer’s disease (AD). In continuation to our previous work on new indole- and/or donepezil-based hybrids as neuroprotective agents, the present study reports on the beneficial effects of lead compounds of the series on key pathognomonic features of AD in both cellular and in vivo models. An enzyme-linked immunosorbent assay (ELISA) was used to evaluate the anti-fibrillogenic properties of 15 selected derivatives and identify quantitative changes in the formation of neurotoxic β-amyloid (Aβ42) species in human neuronal cells in response to treatment. Among the most promising compounds were 3a and 3c, which have recently shown excellent antioxidant and anticholinesterase activities, and, therefore, have been subjected to further in vivo investigation in mice. An acute toxicity study was performed after intraperitoneal (i.p.) administration of both compounds, and 1/10 of the LD50 (35 mg/kg) was selected for subacute treatment (14 days) with scopolamine in mice. Donepezil (DNPZ) and/or galantamine (GAL) were used as reference drugs, aiming to establish any pharmacological superiority of the multifaceted approach in battling hallmark features of neurodegeneration. Our promising results give first insights into emerging disease-modifying strategies to combine multiple synergistic activities in a single molecule.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department "Pharmacology, Pharmacotherapy and Toxicology", Faculty of Pharmacy, Medical University of Sofia, 1431 Sofia, Bulgaria.
- Institute of Neurobiology, Bulgarian Academy of Sciences, 1113 Sofia, Bulgaria.
- Department of Anatomy, Faculty of Medicine, Trakia University, 6003 Stara Zagora, Bulgaria.
ORCID-Profile: Rositsa Mihaylova, Violina T Angelova, Jana Tchekalarova, Dimitrinka Atanasova, Rumyana Simeonova
Förderung
- The Bulgarian National Science Fund
- Bulgarian National Science Fund
Zitieren
APA
Mihaylova, R., Angelova, V. T., Tchekalarova, J., Atanasova, D., Ivanova, P., & Simeonova, R. (2024). Tailored Melatonin- and Donepezil-Based Hybrids Targeting Pathognomonic Changes in Alzheimer’s Disease: An In Vitro and In Vivo Investigation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115969
Vancouver
Mihaylova R, Angelova VT, Tchekalarova J, Atanasova D, Ivanova P, Simeonova R. Tailored Melatonin- and Donepezil-Based Hybrids Targeting Pathognomonic Changes in Alzheimer’s Disease: An In Vitro and In Vivo Investigation. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25115969
BibTeX
@article{Mihaylova2024,
author = {Mihaylova, Rositsa and Angelova, Violina T and Tchekalarova, Jana and Atanasova, Dimitrinka and Ivanova, Petja and Simeonova, Rumyana},
title = {Tailored Melatonin- and Donepezil-Based Hybrids Targeting Pathognomonic Changes in Alzheimer’s Disease: An In Vitro and In Vivo Investigation},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25115969}
}
EUVIMED